{"id":"buprenorphine-naloxone","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Withdrawal symptoms (if inadequately dosed)"}]},"_chembl":null,"_dailymed":{"setId":"4951ec29-609b-4836-b0e4-0d9c1d6ae6fe","title":"BUPRENORPHINE AND NALOXONE FILM [INGENUS PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine binds with high affinity to mu-opioid receptors as a partial agonist, providing sufficient opioid activity to prevent withdrawal and reduce cravings while having a ceiling effect that limits euphoria and overdose risk. Naloxone is included as a mu-opioid antagonist that becomes active if the combination is injected intravenously, discouraging intravenous misuse. Together, this combination is used for opioid use disorder maintenance treatment.","oneSentence":"Buprenorphine acts as a partial mu-opioid agonist while naloxone acts as a mu-opioid antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:19.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder maintenance treatment"},{"name":"Opioid dependence"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07475728","phase":"","title":"EMS-Initiated Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":495},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT06784180","phase":"PHASE4","title":"Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT05180669","phase":"NA","title":"Reward-based Technology to Improve OUD Treatment","status":"TERMINATED","sponsor":"Q2i, LLC","startDate":"2022-11-18","conditions":"Opioid Use Disorder","enrollment":41},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT04771689","phase":"PHASE4","title":"Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-07-01","conditions":"Post-operative Pain","enrollment":""},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT04091009","phase":"PHASE4","title":"Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-10","conditions":"Opioid-use Disorder, Opioid Use Disorder, Mild","enrollment":""},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT05546515","phase":"PHASE2","title":"Suvorexant for Opioid/Stimulant Co-use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-12-01","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":20},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT04464421","phase":"NA","title":"SMART Effectiveness Trial","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2020-08-17","conditions":"Opioid-use Disorder, Opioid Dependence, Treatment Adherence","enrollment":48},{"nctId":"NCT05118204","phase":"PHASE4","title":"Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2022-09-29","conditions":"Substance Use Disorders, Opioid-use Disorder, Chronic Pain","enrollment":23},{"nctId":"NCT06961058","phase":"NA","title":"Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2025-06-03","conditions":"Opioid Use Disorder","enrollment":528},{"nctId":"NCT04161066","phase":"PHASE1","title":"Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-01-13","conditions":"Opioid Use Disorder","enrollment":10},{"nctId":"NCT04600414","phase":"NA","title":"Collaborating to Heal Addiction and Mental Health in Primary Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-16","conditions":"Opioid-use Disorder, Mental Health Disorder","enrollment":254},{"nctId":"NCT04811014","phase":"PHASE4","title":"Young Houston Emergency Opioid Engagement System","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-04-19","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Overdose","enrollment":250},{"nctId":"NCT03396276","phase":"PHASE4","title":"Houston Emergency Opioid Engagement System","status":"ENROLLING_BY_INVITATION","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-04-01","conditions":"Opioid Use Disorder","enrollment":3000},{"nctId":"NCT05450718","phase":"PHASE4","title":"Low-dose Buprenorphine Initiation for Opioid Use Disorder","status":"RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2024-11-11","conditions":"Opioid Use Disorder","enrollment":70},{"nctId":"NCT05944952","phase":"PHASE4","title":"Low-dose Versus a High-dose Sublingual Buprenorphine Induction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2024-06-20","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT05528848","phase":"PHASE1","title":"Multi-System Analysis of Opioid Receptor Binding","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2022-09-20","conditions":"Healthy, Opioid Use Disorder","enrollment":60},{"nctId":"NCT05976646","phase":"PHASE1, PHASE2","title":"Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2023-09-18","conditions":"Addiction, Opioid Use, Substance Use Disorders","enrollment":18},{"nctId":"NCT05121428","phase":"","title":"Patients' Attitudes Toward and Experiences With Buprenorphine Treatment","status":"SUSPENDED","sponsor":"Cambridge Health Alliance","startDate":"2021-11-20","conditions":"Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders","enrollment":817},{"nctId":"NCT04948307","phase":"NA","title":"OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"COMPLETED","sponsor":"Orexo AB","startDate":"2021-06-30","conditions":"Opioid-use Disorder","enrollment":437},{"nctId":"NCT03918850","phase":"PHASE3","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":140},{"nctId":"NCT06087991","phase":"","title":"Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment","status":"COMPLETED","sponsor":"Jerry Cochran","startDate":"2023-04-01","conditions":"Opioid Abuse","enrollment":65},{"nctId":"NCT03773523","phase":"NA","title":"Neuromodulation and Cognitive Training in Opioid Use Disorder","status":"RECRUITING","sponsor":"University of Minnesota","startDate":"2019-08-01","conditions":"Opioid-use Disorder, Opioid Dependence, Opioid Abuse","enrollment":30},{"nctId":"NCT04893525","phase":"PHASE2, PHASE3","title":"Evaluating Buprenorphine/Naloxone Microdosing vs. Standard Dosing in Emergency Departments","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-07-23","conditions":"Opioid-use Disorder","enrollment":658},{"nctId":"NCT04111939","phase":"NA","title":"HEALing Communities Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTI International","startDate":"2019-10-23","conditions":"Opioid Use Disorder (OUD)","enrollment":67},{"nctId":"NCT05790551","phase":"NA","title":"Suboxone Dispenser for OUD","status":"WITHDRAWN","sponsor":"Addinex Technologies, Inc.","startDate":"2024-01-15","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":""},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT05872386","phase":"NA","title":"\"Bupe by the Book\": A Tele-Buprenorphine Clinical Trial in Public Libraries With Unstably Housed Persons With Opioid Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-06-28","conditions":"Telehealth at the Library, Control Group","enrollment":60},{"nctId":"NCT05011266","phase":"PHASE2, PHASE3","title":"Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder","status":"RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-04-18","conditions":"Opioid-use Disorder","enrollment":180},{"nctId":"NCT06494904","phase":"PHASE3","title":"Standard Versus High Dose ED-Initiated Buprenorphine Induction","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-12-06","conditions":"Opioid Use Disorder","enrollment":360},{"nctId":"NCT06288711","phase":"NA","title":"Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2024-06-03","conditions":"Opioid Use Disorder, Posttraumatic Stress Disorder","enrollment":135},{"nctId":"NCT06406400","phase":"PHASE1","title":"Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2024-05-13","conditions":"Opioid Use Disorder","enrollment":15},{"nctId":"NCT03993392","phase":"PHASE4","title":"SUBLOCADE Rapid Initiation Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2019-08-29","conditions":"Opioid-use Disorder","enrollment":26},{"nctId":"NCT04080180","phase":"NA","title":"SMART Trial for Buprenorphine-Naloxone Medication Assisted Treatment Adherence","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2022-02-01","conditions":"Opioid-use Disorder","enrollment":332},{"nctId":"NCT05733442","phase":"NA","title":"Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation","status":"RECRUITING","sponsor":"Washington State University","startDate":"2023-01-17","conditions":"Opioid Use Disorder","enrollment":136},{"nctId":"NCT06089707","phase":"PHASE3","title":"Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-01-09","conditions":"Opioid Use Disorder","enrollment":25},{"nctId":"NCT04447287","phase":"PHASE1","title":"A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2020-06-29","conditions":"Opioid Use Disorder","enrollment":23},{"nctId":"NCT04818086","phase":"PHASE1, PHASE2","title":"Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2021-05-03","conditions":"Drug Interaction, Analgesics, Opioid Use Disorder","enrollment":18},{"nctId":"NCT04737603","phase":"PHASE2","title":"Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"University of California, Davis","startDate":"2025-07-30","conditions":"Opioid-use Disorder","enrollment":""},{"nctId":"NCT05062577","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-11-08","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03718104","phase":"","title":"MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2018-12-01","conditions":"Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk","enrollment":46},{"nctId":"NCT04253782","phase":"NA","title":"SafetyNet Program for Opioid Use Disorder (OUD)","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-01","conditions":"Opioid-Use Disorder (OUD)","enrollment":81},{"nctId":"NCT03908437","phase":"PHASE4","title":"Rapid Initiation of Drug Treatment Engagement","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-07-15","conditions":"Opioid-use Disorder, Overdose","enrollment":104},{"nctId":"NCT04976855","phase":"PHASE1","title":"Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2022-08-17","conditions":"Healthy Volunteer, Opioid-use Disorder","enrollment":64},{"nctId":"NCT05644587","phase":"PHASE4","title":"Novel Induction to Buprenorphine/Naloxone","status":"TERMINATED","sponsor":"Bicycle Health","startDate":"2023-02-06","conditions":"Opioid Use Disorder, Opioid Use, Opioid Abuse","enrollment":33},{"nctId":"NCT04480554","phase":"PHASE2","title":"Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-01-30","conditions":"Opioid-use Disorder, HIV-1-infection, Immune Activation","enrollment":225},{"nctId":"NCT04234191","phase":"PHASE2","title":"Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-08-18","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT04794790","phase":"EARLY_PHASE1","title":"Buprenorphine Induction for Fentanyl Dependent Opioid Users","status":"WITHDRAWN","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-09","conditions":"Opioid Dependence Fentanyl","enrollment":""},{"nctId":"NCT04283500","phase":"PHASE4","title":"Buprenorphine Loading in the Emergency Department","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-11-01","conditions":"Opioid-use Disorder","enrollment":15},{"nctId":"NCT03291847","phase":"PHASE2","title":"Maternal Buprenorphine-naloxone Treatment and the Infant","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Maternal Opioid Use Disorder, Opioid Exposed Infant","enrollment":42},{"nctId":"NCT04049799","phase":"","title":"Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions","status":"COMPLETED","sponsor":"University of Vermont","startDate":"2019-08-08","conditions":"Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome","enrollment":88},{"nctId":"NCT05164549","phase":"PHASE3","title":"Extended-release Pharmacotherapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"King's College London","startDate":"2019-08-06","conditions":"Opiate Substitution Treatment","enrollment":342},{"nctId":"NCT02093559","phase":"NA","title":"Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients","status":"COMPLETED","sponsor":"San Francisco Department of Public Health","startDate":"2014-07","conditions":"Opioid-Related Disorders, Drug Overdose","enrollment":63},{"nctId":"NCT03976258","phase":"","title":"Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2017-07-14","conditions":"HIV Infection, Opioid-use Disorder, Cardiovascular Diseases","enrollment":190},{"nctId":"NCT03769025","phase":"PHASE1, PHASE2","title":"Remote Observed Dosing of Suboxone to Improve Clinical Practice","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-04-01","conditions":"Opioid-use Disorder, Opioid Dependence, Opiate Dependence","enrollment":16},{"nctId":"NCT04716413","phase":"PHASE4","title":"Evaluating the Use of Sublingual Sufentanil in Patients With Suboxone Treatment","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2021-09-27","conditions":"Acute Pain","enrollment":3},{"nctId":"NCT03699085","phase":"NA","title":"Emergency Department Longitudinal Integrated Care","status":"COMPLETED","sponsor":"University of Washington","startDate":"2018-12-11","conditions":"Opioid-use Disorder, Emergency Department","enrollment":40},{"nctId":"NCT04521920","phase":"NA","title":"Providing Suboxone and PrEP Using Telemedicine","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-11-09","conditions":"Opioid Use, Opioid-use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT01843751","phase":"PHASE3","title":"Dane County Drug Court Study for Addicted Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2013-03","conditions":"Opioid Dependence","enrollment":24},{"nctId":"NCT01082679","phase":"PHASE2, PHASE3","title":"Treatment for Opioid Dependent Offenders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2009-06","conditions":"Opioid Dependence","enrollment":16},{"nctId":"NCT03026790","phase":"PHASE2","title":"Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2017-10-19","conditions":"Chronic Pain","enrollment":820},{"nctId":"NCT05307458","phase":"","title":"Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing","status":"UNKNOWN","sponsor":"United Health Services Hospitals, Inc.","startDate":"2022-07-01","conditions":"Opioid Use Disorder, Opioid Withdrawal","enrollment":20},{"nctId":"NCT05108935","phase":"NA","title":"Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-02-17","conditions":"Opioid Use, Opioid Use Disorder, Risk Reduction","enrollment":17},{"nctId":"NCT04991974","phase":"PHASE2, PHASE3","title":"Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine","status":"UNKNOWN","sponsor":"Friends Research Institute, Inc.","startDate":"2021-09-17","conditions":"Opioid-use Disorder","enrollment":360},{"nctId":"NCT00684073","phase":"PHASE4","title":"Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2007-07","conditions":"Opiate-related Disorders, Opiate Dependence, Drug Abuse","enrollment":60},{"nctId":"NCT04656899","phase":"NA","title":"Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study","status":"COMPLETED","sponsor":"Washington State University","startDate":"2020-12-06","conditions":"Opioid-use Disorder","enrollment":41},{"nctId":"NCT02187198","phase":"PHASE3","title":"Buprenorphine Treatment for Opioid Dependence","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-03","conditions":"Opioid Dependence","enrollment":9},{"nctId":"NCT05179772","phase":"PHASE2","title":"Olanzapine in OUD Patients","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2022-07-28","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT03580902","phase":"PHASE1, PHASE2","title":"CBT4CBT for Office Based Buprenorphine","status":"COMPLETED","sponsor":"CBT4CBT, LLC","startDate":"2019-01-22","conditions":"Opioid-use Disorder","enrollment":51},{"nctId":"NCT03711318","phase":"PHASE3","title":"Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2018-11-01","conditions":"Heroin Dependence","enrollment":8},{"nctId":"NCT04464512","phase":"PHASE4","title":"Suboxone User Perioperative Early Referral and Enhanced Recovery After Surgery- Orthopaedic Trauma Surgery Population","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2020-01-10","conditions":"Addiction Opiate, Chronic Pain, Fractures, Bone","enrollment":""},{"nctId":"NCT05594121","phase":"PHASE4","title":"Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder","status":"UNKNOWN","sponsor":"Royal Victoria Hospital, Canada","startDate":"2022-12","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":90},{"nctId":"NCT04139213","phase":"PHASE2, PHASE3","title":"Medication Maintenance Therapy in Community Pharmacy Settings","status":"UNKNOWN","sponsor":"Lifespan","startDate":"2019-07-25","conditions":"Opioid-use Disorder","enrollment":250},{"nctId":"NCT02696096","phase":"PHASE3","title":"Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence","status":"COMPLETED","sponsor":"Butler Hospital","startDate":"2016-08","conditions":"Opioid Addiction","enrollment":21},{"nctId":"NCT02543944","phase":"PHASE2, PHASE3","title":"Improving Treatment Outcomes for Prescription Opioid Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2016-02","conditions":"Drug Dependence","enrollment":117},{"nctId":"NCT03658642","phase":"NA","title":"Clinical Decision Support to Implement ED-initiated Buprenorphine for OUD","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-11-15","conditions":"Clinical Decision Support, Buprenorphine, Opioid-use Disorder","enrollment":5047},{"nctId":"NCT03744663","phase":"PHASE2","title":"Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2022-06","conditions":"Opioid Use","enrollment":""},{"nctId":"NCT00929253","phase":"NA","title":"Efficacy of Computer Delivered Community Reinforcement Approach (CRA) (Bup II)","status":"COMPLETED","sponsor":"Virginia Polytechnic Institute and State University","startDate":"2007-09","conditions":"Opiate Addiction","enrollment":170},{"nctId":"NCT01936857","phase":"PHASE4","title":"Buprenorphine to Improve HIV Care Engagement and Outcomes","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2015-07","conditions":"HIV, Substance Related Disorders","enrollment":281},{"nctId":"NCT05368675","phase":"PHASE4","title":"Medication-assisted Treatment for Injecting Drug Users in Vietnam","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-12-18","conditions":"Opioid Use Disorder, HIV Infections","enrollment":448},{"nctId":"NCT03818399","phase":"PHASE3","title":"Virginia Opioid Overdose Treatment InitiatVE","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2019-01-04","conditions":"Opioid Use Disorder","enrollment":19}],"_emaApprovals":[],"_faersSignals":[{"count":690,"reaction":"NAUSEA"},{"count":400,"reaction":"DRUG WITHDRAWAL SYNDROME"},{"count":363,"reaction":"VOMITING"},{"count":354,"reaction":"HEADACHE"},{"count":328,"reaction":"DRUG DEPENDENCE"},{"count":295,"reaction":"DRUG INEFFECTIVE"},{"count":251,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":219,"reaction":"DRUG ABUSE"},{"count":198,"reaction":"DENTAL CARIES"},{"count":198,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Suboxone"],"phase":"marketed","status":"active","brandName":"Buprenorphine Naloxone","genericName":"Buprenorphine Naloxone","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine acts as a partial mu-opioid agonist while naloxone acts as a mu-opioid antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse. Used for Opioid use disorder maintenance treatment, Opioid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}